Compare 10X Genomics Inc (TXG) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs US Bancorp — how do they compare? 10X Genomics Inc trades at $78.6 (market cap $9.92B), while US Bancorp trades at $57.3 (market cap $87.52B). The key difference: US Bancorp is far larger — about 8.8× 10X Genomics Inc's market cap, and US Bancorp pays a 3.85% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and US Bancorp for 97 Days on average.
| TXG | USB | |
|---|---|---|
Market Cap | $9.92B | $87.52B |
Volume | 9,372,166 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $97.74 | $65.42 |
52-Week Low | $11.48 | $45.28 |
Typical Hold Time | 92 Days | 97 Days |
Enterprise Value | $9.44B | $117.01B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
U.S. Bancorp (USB) trades at $57.03, down 0.45% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.35 exceeding expectations by 5.5%. Revenue growth accelerated to $28.54B in 2025 with net income margin improving to 27.61%. Analyst consensus remains positive with 51% buy ratings and $69.94 price target representing 23% upside potential.
USB presents a value opportunity with attractive valuation multiples (P/E 11.21, P/B 1.44) and dividend yield of 3.8%. Near-term risks include technical weakness and regulatory uncertainties, but strong fee revenue growth and capital markets performance support the bullish fundamental case. The stock offers income appeal with sustainable dividend growth and clean loan portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
